These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17898810)

  • 21. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
    Soria JC; Mok TS; Cappuzzo F; Jänne PA
    Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
    Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
    Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
    [No Abstract]   [Full Text] [Related]  

  • 24. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
    Porta R; Sánchez-Torres JM; Paz-Ares L; Massutí B; Reguart N; Mayo C; Lianes P; Queralt C; Guillem V; Salinas P; Catot S; Isla D; Pradas A; Gúrpide A; de Castro J; Polo E; Puig T; Tarón M; Colomer R; Rosell R
    Eur Respir J; 2011 Mar; 37(3):624-31. PubMed ID: 20595147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
    Bartolotti M; Franceschi E; Brandes AA
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1429-35. PubMed ID: 23249107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
    Alam N; Gustafson KS; Ladanyi M; Zakowski MF; Kapoor A; Truskinovsky AM; Dudek AZ
    Clin Lung Cancer; 2010 Sep; 11(5):E1-4. PubMed ID: 20837450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
    Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
    J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-small cell lung cancer-smokers or non-smokers, does it matter?
    Barlési F; Nanni-Metellus I; Breen D; Fina F; Astoul P; Martin PM
    Lung Cancer; 2009 Mar; 63(3):430-2. PubMed ID: 18789554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
    J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 35. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
    Giaccone G; Gallegos Ruiz M; Le Chevalier T; Thatcher N; Smit E; Rodriguez JA; Janne P; Oulid-Aissa D; Soria JC
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6049-55. PubMed ID: 17062680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
    Popat S; Hughes S; Papadopoulos P; Wilkins A; Moore S; Priest K; Meehan L; Norton A; O'Brien M
    Lung Cancer; 2007 Apr; 56(1):135-7. PubMed ID: 17157952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
    Garfield D
    J Thorac Oncol; 2006 Oct; 1(8):859-60. PubMed ID: 17409972
    [No Abstract]   [Full Text] [Related]  

  • 38. A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
    Huang J; Dong XR; Lu HD; Liu L
    West Indian Med J; 2012 Jan; 61(1):106-8. PubMed ID: 22808577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
    Benedetti G; Latini L; Galetta D; Colucci G; Crinò L
    J Thorac Oncol; 2009 Jul; 4(7):936-7. PubMed ID: 19550250
    [No Abstract]   [Full Text] [Related]  

  • 40. Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?
    Chamberlain MC
    J Clin Oncol; 2013 Sep; 31(25):3164-5. PubMed ID: 23897966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.